Physician profile
Eric Lup-Sing Lo
NPI 1497782023
$10,976.47
in general payments reported to CMS, 2019-2025
28 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $1,661 · 2021: $1,287 · 2022: $3,640 · 2023: $1,234 · 2024: $1,368 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,162 · Travel and Lodging: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,161.80 |
| Travel and Lodging | $1,697.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $3,356.92 | 2020-2022 | |
| Abbott Laboratories | $1,943.21 | 2021-2025 | Diamondback Peripheral, Aveir, Jot Dx |
| Medtronic, INC. | $1,419.12 | 2021-2025 | Corevalve Evolut R, Linq II, Crome Dr Mri Surescan |
| Cardiovascular Systems INC. | $1,075.02 | 2019-2023 | Diamondback Coronary |
| Boston Scientific Corporation | $713.95 | 2019-2025 | General - Tachy, Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Philips North America LLC | $648.18 | 2025 | IV Other, Igt Devices Undivided |
| Biotronik INC. | $430.83 | 2019-2021 | |
| Abiomed | $183.12 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $172.68 | 2019-2025 | Lifevest |
| Biosense Webster, INC. | $171.58 | 2024-2025 | Carto 3 |
| Atricure, INC. | $140.15 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax, Epi-Ease Epicardial Access System, Atriclip Laa Exclusion System |
| Amgen INC. | $129.03 | 2019-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $82.77 | 2022 | |
| Merck Sharp & Dohme LLC | $64.54 | 2022-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.64 | 2024 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $47.41 | 2021-2022 | |
| Novo Nordisk INC | $41.13 | 2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $40.69 | 2024 | |
| Janssen Pharmaceuticals, INC | $39.91 | 2022 | |
| Ascensia Diabetes Care US INC. | $36.97 | 2025 | |
| Teleflex LLC | $29.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.96 | 2022 | |
| Bridgebio Pharma, INC. | $27.09 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $26.63 | 2022 | |
| Pfizer INC. | $26.31 | 2022 | |
| Lantheus Medical Imaging, INC. | $23.86 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.52 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $10.00 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.